Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 25 phantom stock units on April 30, 2025, according to a Form 4 filing with the SEC.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on April 30, 2025.
• Bourla acquired 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price of the phantom stock units was $24.41.
• Following the transaction, Bourla directly owns 705,968 shares of Pfizer common stock.
• The phantom stock units are settled in cash after Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The phantom stock units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units and is part of the CEO's compensation package.
• It provides transparency to shareholders regarding executive compensation.

Key Dates

Keywords

Form 4, Albert Bourla, Pfizer, Phantom Stock Units, SEC Filing, Insider Transaction, Deferred Compensation